Phase II Trial of @entity1206 and XXXX Chemotherapy in Advanced @entity1149 .

@entity1 @entity1665 @entity137 @entity390 @entity417 @entity1149 @entity900 @entity391 @entity1206 @entity1431 @entity902 @entity2359
PURPOSE: @entity902 -based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in @entity1 with advanced @entity1149 ( @entity1149 ). We performed a phase II trial in order to evaluate the efficacy and @entity137 of combination chemotherapy with @entity1206 ( @entity1206 ) and @entity900 in advanced @entity1149 . MATERIALS AND METHODS: @entity1 with previously untreated, unresectable stage IIIB or IV @entity1149 with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous @entity1206 25 mg/m2, on day 1 and 8, and intravenous @entity900 80 mg/m2 on day 1; this cycle was repeated every three weeks. RESULTS: A total of 33 @entity1 were enrolled in the study between July 1999 and Feb 2000. Of the 30 @entity1 deemed eligible for analysis, thirteen @entity1 achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 @entity137 were @entity417 in 1.5%, @entity1431 in 4.5%, @entity390 / @entity391 in 2.3%, @entity1665 in 13.3%, and @entity2359 in 3.3%. CONCLUSION: The combination of @entity1206 and @entity900 chemotherapy seems to be active and fairly tolerable in @entity1 with advanced @entity1149 .
